Faculty Collaboration Database

First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma. Oncologist 2018 Jul;23(7):840-843

Date

04/21/2018

Pubmed ID

29674442

Pubmed Central ID

PMC6058337

DOI

10.1634/theoncologist.2017-0561

Scopus ID

2-s2.0-85050506456 (requires institutional sign-in at Scopus site)   11 Citations

Abstract

Checkpoint inhibitors targeted at programmed cell death-1 receptor (PD-1) and its ligand (PD-L1) can result in significant benefit to a small proportion of patients with cancer, including those with tumors of the stomach and gastroesophageal junction. These drugs are now approved for several solid tumors, including the recent accelerated approval of pembrolizumab for gastroesophageal adenocarcinomas in the third-line setting and beyond based on the KEYNOTE-059 phase II trial. Data are lacking on the efficacy of chemotherapy after progression on PD-1 blockade in metastatic gastroesophageal adenocarcinoma. This report describes the exceptional response of two patients who received ramucirumab plus paclitaxel after progressive disease on pembrolizumab. This early clinical observation suggests that the sequence of administration of PD-1 blockade and chemotherapy may be important in this disease.

Author List

Chakrabarti S, Dong H, Paripati HR, Ross HJ, Yoon HH

MESH terms used to index this publication - Major topics in bold

Adenocarcinoma
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Disease Progression
Esophageal Neoplasms
Female
Humans
Male
Middle Aged
Paclitaxel
Stomach Neoplasms